Cargando…

Limited sampling strategies for estimation of tacrolimus exposure in kidney transplant recipients receiving extended‐release tacrolimus preparation

Tacrolimus is the key component of most contemporary immunosuppressive drug regimens for the prevention of transplant rejection. Area under the concentration time curve over 24 h (AUC(0–24)) predicts efficacy, but predose (trough) tacrolimus blood concentration (C(0)) is currently used to guide dosi...

Descripción completa

Detalles Bibliográficos
Autores principales:	El‐Nahhas, Toqa, Popoola, Joyce, MacPhee, Iain, Johnston, Atholl
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742643/ https://www.ncbi.nlm.nih.gov/pubmed/34780122 http://dx.doi.org/10.1111/cts.12990

Ejemplares similares

Efficacy and safety of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate‐ or prolonged‐release tacrolimus
por: Vondrak, Karel, et al.
Publicado: (2019)

Evaluation of Flexible Tacrolimus Drug Concentration Monitoring Approach in Patients Receiving Extended‐Release Once‐Daily Tacrolimus Tablets
por: Philosophe, Benjamin, et al.
Publicado: (2018)

The Effect of Intracellular Tacrolimus Exposure on Calcineurin Inhibition in Immediate- and Extended-Release Tacrolimus Formulations
por: Fontova, Pere, et al.
Publicado: (2023)

Additive Manufacturing of an Extended-Release Tablet of Tacrolimus
por: Abdollahi, Azin, et al.
Publicado: (2023)

Conversion From Twice-Daily Tacrolimus Capsules to Once-Daily Extended-Release Tacrolimus (LCPT): A Phase 2 Trial of Stable Renal Transplant Recipients
por: Gaber, A. Osama, et al.
Publicado: (2013)

Evaluation of limited sampling strategies for tacrolimus
por: Op den Buijsch, Robert A. M., et al.
Publicado: (2007)

Conversion From Twice-Daily Tacrolimus to Once-Daily Extended Release Tacrolimus (LCPT): The Phase III Randomized MELT Trial
por: Bunnapradist, S, et al.
Publicado: (2013)

Long-Term Follow-Up of a Phase III Clinical Trial Comparing Tacrolimus Extended-Release/MMF, Tacrolimus/MMF, and Cyclosporine/MMF in De Novo Kidney Transplant Recipients
por: Silva, Hélio Tedesco, et al.
Publicado: (2014)

A Randomized Pharmacokinetic Study of Generic Tacrolimus Versus Reference Tacrolimus in Kidney Transplant Recipients
por: Alloway, R R, et al.
Publicado: (2012)

Effect of Concentration/Dose Ratio in De Novo Kidney Transplant Recipients Receiving LCP-Tacrolimus or Immediate-Release Tacrolimus: Post Hoc Analysis of a Phase 3 Clinical Trial
por: Suwelack, Barbara, et al.
Publicado: (2020)

Evaluation of limited-sampling strategies to calculate AUC((0–24)) and the role of CYP3A5 in Chilean pediatric kidney recipients using extended-release tacrolimus
por: Galvez, Carla, et al.
Publicado: (2023)

Once-Daily Tacrolimus Extended-Release Formulation: 1 Year after Conversion in Stable Pediatric Kidney Transplant Recipients
por: Pape, Lars, et al.
Publicado: (2011)

Improved Medication Adherence with the Use of Extended-Release Tacrolimus in Liver Transplant Recipients: A Pilot Randomized Controlled Trial
por: Verma, Manisha, et al.
Publicado: (2023)

Tacrolimus trough levels in kidney transplant recipients
por: Hwang, Young Hui, et al.
Publicado: (2021)

Renal Function in De Novo Liver Transplant Recipients Receiving Different Prolonged‐Release Tacrolimus Regimens—The DIAMOND Study
por: TruneČka, P., et al.
Publicado: (2015)

Real-World Study of Once-Daily, Extended-Release Tacrolimus Versus Twice-Daily, Immediate-Release Tacrolimus in Kidney Transplantation: Clinical Outcomes and Healthcare Resource Utilization
por: Ho, Bing, et al.
Publicado: (2019)

A comparison of the extended-release and standard-release formulations of tacrolimus in de novo kidney transplant recipients: a 12-month outcome study
por: Fanous, Helen, et al.
Publicado: (2013)

Effectiveness and safety of the conversion to MeltDose(®) extended‐release tacrolimus from other formulations of tacrolimus in stable kidney transplant patients: A retrospective study
por: Sánchez Fructuoso, Ana, et al.
Publicado: (2019)

Immunological risk stratification and tailored minimisation of immunosuppression in renal transplant recipients
por: Phanish, Mysore K., et al.
Publicado: (2020)

Clinical Pharmacokinetics of Tacrolimus in Iranian Liver Transplant Recipients
por: Nasiri-Toosi, Zahra, et al.
Publicado: (2014)

Gout Due to Tacrolimus in a Liver Transplant Recipient
por: Afridi, Summia Matin, et al.
Publicado: (2019)

A randomized cross-over comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers
por: Zaltzman, Jeffrey S, et al.
Publicado: (2014)

Preparation and In Vitro Evaluation of Tacrolimus-Loaded Ethosomes
por: Li, Guiling, et al.
Publicado: (2012)

Population pharmacokinetics of immediate‐ and prolonged‐release tacrolimus formulations in liver, kidney and heart transplant recipients
por: Lu, Zheng, et al.
Publicado: (2019)

Patient involvement in selection of immunosuppressive regimen following transplantation
por: Popoola, Joyce, et al.
Publicado: (2014)

Impacts of High Intra- and Inter-Individual Variability in Tacrolimus Pharmacokinetics and Fast Tacrolimus Metabolism on Outcomes of Solid Organ Transplant Recipients
por: Thongprayoon, Charat, et al.
Publicado: (2020)

A randomized crossover study comparing different tacrolimus formulations to reduce intrapatient variability in tacrolimus exposure in kidney transplant recipients
por: Bunthof, Kim L. W., et al.
Publicado: (2021)

Epidermal Cysts in a Tacrolimus Treated Renal Transplant Recipient
por: Ahn, In Su, et al.
Publicado: (2011)

Systematic conversion to generic tacrolimus in stable kidney transplant recipients
por: Rosenborg, Staffan, et al.
Publicado: (2014)

Massive pleural effusion in a renal transplant recipient on tacrolimus
por: Nayagam, L. S., et al.
Publicado: (2014)

Pharmacokinetics of tacrolimus according to body composition in recipients of kidney transplants
por: Han, Seung Seok, et al.
Publicado: (2012)

Tacrolimus Levels Are Not Associated with Risk of Malignancy in Lung Transplant Recipients
por: Fox, Benjamin Daniel, et al.
Publicado: (2017)

Pharmacokinetics of apixaban and tacrolimus or cyclosporine in kidney and lung transplant recipients
por: Mansell, Holly, et al.
Publicado: (2022)

Body composition is associated with tacrolimus pharmacokinetics in kidney transplant recipients
por: Francke, M. I., et al.
Publicado: (2022)

Tacrolimus Formulation, Exposure Variability, and Outcomes in Kidney Transplant Recipients
por: Lai, Elaine F., et al.
Publicado: (2022)

HMG-CoA reductase inhibitors in kidney transplant recipients receiving tacrolimus: statins not associated with improved patient or graft survival
por: Younas, Nizar, et al.
Publicado: (2010)

An interaction between tacrolimus and pristinamycin resulting in an elevated tacrolimus level
por: Tehan, Jane V., et al.
Publicado: (2011)

Tacrolimus: COVID-19 and toxic levels of tacrolimus: case report
Publicado: (2021)

Efficacy and safety of prolonged‐release tacrolimus in stable pediatric allograft recipients converted from immediate‐release tacrolimus – a Phase 2, open‐label, single‐arm, one‐way crossover study
por: Rubik, Jacek, et al.
Publicado: (2019)

Conversion from Standard-Release Tacrolimus to MeltDose(®) Tacrolimus (LCPT) Improves Renal Function after Liver Transplantation
por: von Einsiedel, Johannes, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_l3fi00v5nuhv8q5dd0ljn99f4n